by: TN Media News:
The Saudi Society of Dermatology and Dermatologic Surgery (SSDDS), the leading professional body for dermatologists in Saudi Arabia, has signed a Memorandum of Understanding (MoU) with AbbVie Saudi Arabia, a global biopharmaceutical research and development company, and Al Nahdi Medical Company, the largest retail pharmacy chain in the Middle East and Africa. The MoU aims to foster collaboration in enhancing public health services, launching awareness programs, and advancing disease management through innovative healthcare solutions. It also seeks to strengthen the role of SSDDS by encouraging partnerships between public and private entities, supporting the goals of Saudi Vision 2030.
Dr. Abdullah Al-Aqeel, President of SSDDS, stated that the primary focus of the MoU is to collaborate on patient education and awareness campaigns, particularly related to psoriasis and atopic dermatitis—their symptoms, treatment options, and overall management. The initiative also aims to provide patients with access to accurate, culturally relevant educational materials. In addition, the MoU includes training and support for healthcare professionals through workshops and educational sessions organized in collaboration with SSDDS, to equip dermatologists and healthcare providers with the latest knowledge on treatment developments for these conditions.
Dr. Maysa Ashmawy, Head of Dermatology at the Saudi Ministry of Health and a board member of SSDDS, emphasized the importance of such partnerships in improving healthcare services and supporting research initiatives in collaboration with SSDDS. She also highlighted the value of sharing clinical insights with healthcare providers to support national public health goals.
Dr. Afaf Al-Sheikh, Consultant and Head of the Dermatology Department at King Abdulaziz Medical City, National Guard, welcomed the signing of the MoU. She noted that the agreement establishes a collaborative framework to advance the management of psoriasis and atopic dermatitis in Saudi Arabia. Dr. Al-Sheikh emphasized the need to increase awareness, promote early diagnosis and treatment, and improve access to high-quality care in alignment with Saudi Vision 2030. She added that SSDDS continues to fulfill its developmental and training mission by organizing professional training sessions, facilitating research initiatives, and sharing insights on disease management trends.
Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, reaffirmed AbbVie’s commitment to working with healthcare authorities in the Kingdom to support awareness programs, provide training resources, and enhance education for healthcare professionals. He stated that AbbVie’s mission is to discover and deliver innovative medicines and solutions that address today’s serious health issues and prepare for future medical challenges. The company strives to make a meaningful impact on patients’ lives, particularly in key therapeutic areas such as immunology, oncology, and neuroscience.
